Buy & Sell Becton Dickinson and Co (BDX) – Becton Dickinson and Co Price Today
Aura AI Summary
Key Stats
- $40.49BMarket Cap
- HealthSector
- -22.78%3M Drawdown
- $56.95BEnterprise Value
- 2.86%Dividend Yield
- 99% Buy | 1% SellTrading Activity
- 90 daysTypical Hold Time
Becton Dickinson and Co (BDX) is currently valued at a market capitalization of $40.49B, with an enterprise value of $56.95B. Over the past 52 weeks, Becton Dickinson and Co has traded between a low of $132.35 and a high of $185.39, highlighting its annual price range. Over the past three months, Becton Dickinson and Co has recorded a drawdown of -22.78%, reflecting recent price volatility. Becton Dickinson and Co offers a dividend yield of 2.86%, with the most recent dividend of $1.05 paid on 10 Mar 26. On average, investors hold Becton Dickinson and Co for approximately 90 days, indicating typical investor behavior on the platform.
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Most Recent News
BlackSky to present at three key investor conferences in May and June 2026
BlackSky Technology Inc. announced its participation in three upcoming investor conferences: the Jefferies Virtual Space Summit on May 26, the 23rd Annual Craig-Hallum Institutional Investor Conference on May 28, and the Morgan Stanley National Secur...

LiquidStack launches GigaModular™ liquid cooling platform with 14 MW capacity for AI data centers
LiquidStack, a Trane Technologies company, has commercially launched its GigaModular™ CDU platform designed for high-density AI data centers. The platform offers flexible, scalable liquid cooling capacity up to 14 MW, enabling operators to expand coo...

Inventiva to present at 2026 Jefferies Global Healthcare Conference in June
Inventiva, a biopharmaceutical company developing oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), announced its CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3. The ...
